ClinicalTrials.gg
CompletedNCT00647946RAVEUpdated Jun 30, 2008

Study to Evaluate Changes in Limb Fat When Switching From a Thymidine Analogue

A Phase 2 interventional study of tenofovir DF and abacavir 300mg twice daily in Lipodystrophy, sponsored by Gilead Sciences. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-06-30.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

A previous study substituting zidovudine or stavudine to abacavir in patients with severe or moderate lipoatrophy has shown an increase in limb fat by DEXA. This study was conducted over a 24-week period and although improved outcomes were documented by objective measures, DEXA scans, subjective observation did not correspond. Longer-term follow up of these patients is required.

This 48 week study is designed to compare the substitution of the thymidine analogues zidovudine (ZDV) or stavudine (D4T) with either tenofovir DF or abacavir, in patients treated with highly active antiretroviral therapy (HAART), and show improved outcomes on total limb fat mass, improved body shape by dual energy x-ray absorptiometry (DEXA) and computed tomography (CT) scans and improved cholesterol and triglycerides.

Read the detailed description

This is a phase II, open-label, multicentre, randomised, two-arm study of 48 weeks duration. One hundred HIV infected individuals who have documented lipodystrophy at > 1 body/facial site and currently receiving zidovudine (ZDV) or stavudine (d4T) will be recruited.

02

Conditions studied

  • Lipodystrophy

Browse trials for

Keywords

  • lipodystrophy
03

In context

Lipodystrophy

140 studies on the registry are indexed under Lipodystrophy; 11 are open to participants now.

This study's enrollment of 100 is above the median of 46 across 97 interventional studies indexed under Lipodystrophy.

Browse Lipodystrophy studies →

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who are male or female > 18 years of age
  • Subjects who are -1 infected as documented by a licensed HIV-1 antibody ELISA
  • Female subjects of must have a negative serum pregnancy test (beta-HCG) within 28 days of trial day 1. Women of childbearing potential must agree to use a barrier method of
  • Female subjects must not be pregnant or lactating
  • Subjects who in the opinion of the investigator have the ability to understand and provided written to participate in the trial
  • Subjects who in the opinion of the investigator have clinical lipoatrophy at > 1 body/facial site
  • Subjects currently receiving nucleoside analogue regimen including stavudine (d4T) or zidovudine (ZDV)
  • Subjects who are stable on current therapy for >16 weeks
  • Subjects with no prior exposure to tenofovir, abacavir, or adefovir
  • Subjects with no known K65R, 69S mutations or 3 or more thymidine analogue mutations
  • Subjects with documented viral load \<50 copies/ml on 2 consecutive occasions including most recent clinic attendance

Exclusion criteria

Exclusion Criteria:

  • Subjects who in the investigator's opinion are unlikely to complete the 48 week trial period
  • Currently active opportunistic disease or documented wasting syndrome
  • Currently receiving chemotherapy for
  • Subjects who in the opinion of the investigator are unlikely to retain viral response after switching based on treatment or transmission history
  • Currently receiving an insulin sensitising agent (glitazone or metformin)
  • Anabolic steroids in the last 16 weeks other than testosterone at replacement doses (\<250mg/2 weekly)
  • Growth hormone use in the last 16 weeks
  • Statin therapy (HMG CoA reductase inhibitor) commenced in the last 16 weeks (patients stable on statins my be included)
  • Current alcohol or illicit drug use which, in the opinion of the investigator, may interfere with the subjects' ability to comply with the dosing schedule and protocol evaluations
  • Receiving concurrent medications that - in the opinion of the investigator and according to drug product labelling - will result in interactions with tenofovir or abacavir
  • Pregnant or breast feeding
  • Previously received more than 3 months zidovudine monotherapy
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    A

    Stop zidovudine (ZDV) or stavudine (d4T) and start tenofovir DF 300mg once daily along with the other antiviral drugs that are used as part of their HAART regimen

    Drug: tenofovir DF

  • Active comparator
    B

    Stop zidovudine (ZDV) or stavudine (d4T) and start abacavir 300mg twice daily along with the other antiviral drugs that are used as part of their HAART regimen

    Drug: abacavir 300mg twice daily

Interventions

06

What researchers measure

Primary outcomes

  1. Change in total limb fat mass by DEXA scan

    Time frame: 24 and 48 weeks

Secondary outcomes

  1. Change in VAT by single slice L4 abdominal CT scan

    Time frame: 24 and 48 weeks

  2. Change in viral load measurements and CD4 cell count

    Time frame: 24 and 48 Weeks

  3. Change in fasting cholesterol and triglycerides

    Time frame: 24 and 48 Weeks

  4. Change in blood insulin and fasting glucose

    Time frame: 24 and 48 Weeks

  5. Change in blood lactate and anion gap

    Time frame: 24 and 48 Weeks

  6. Change in bone mineral density by DEXA scan

    Time frame: 24 and 48 Weeks

  7. Incidence of adverse events

    Time frame: Upto 48 weeks

07

Study locations

1 site
  • Gilead Sciences
    Abingdon, Cambridge CB1 6GT, United Kingdom
08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2003, a primary completion of Oct 2004 and a completion of Feb 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2008
First posted
Apr 1, 2008
Start
Feb 2003
Primary completionActual
Oct 2004
CompletionActual
Feb 2006
Last update
Jun 30, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00647946
Lead sponsor
Gilead Sciences
First posted
Apr 1, 2008
Start date
Feb 2003
Primary completion
Oct 2004
Completion
Feb 2006
Last update
Jun 30, 2008

Study contacts

Geoff Cotton
study director · Gilead Sciences

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenofovir

Start the discussion